Rendering of Bristol Myers Squibb’s planned $2.3 billion state-of-the-art manufacturing campus in Houston, Texas. [Image courtesy of BMS]
The campus, at Generation Park in Houston, will create nearly 500 skilled jobs, the company said.
The campus’ multi-modal capabilities will allow BMS to manufacture multiple types of medicines – such as small molecules, biologics and antibody-drug conjugates – across a range of disease areas, supporting drug product and finished goods manufacturing from late development through launch, the company said.
“This investment reflects our confidence in America’s continued leadership in biopharmaceutical innovation,” Christopher Boerner, Ph.D., Board Chair and CEO, said in a press release. “As part of our $40 billion commitment to the United States, we’re building the domestic manufacturing capabilities needed to deliver the next generation of medicines and support future scientific breakthroughs.”
Boerner announced the company’s $40 billion commitment to manufacturing in the U.S. in an op-ed in STAT last year as Eli Lilly, Johnson & Johnson and others made similar commitments in response to President Donald Trump’s threats of pharma tariffs, which he said would be waived for companies with onshore manufacturing capabilities.
“Texas is a global hub for life sciences, where today’s innovations shape the future of healthcare,” Texas Gov. Greg Abbott said in a press release. “This $2.3 billion investment by Bristol Myers Squibb in the dynamic biotech ecosystem in Houston is a testament to the depth of our skilled workforce and the pipeline of talent coming through our nation-leading technical colleges and research universities.”
BMS also expects to create approximately 2,000 construction and other indirect jobs between 2027–2030 as the facility is built and brought online, supporting the local economy throughout the construction period, the company said.
The company currently works with a Contract Manufacturer in Texas for both commercial and clinical trial manufacturing and, in 2025, had 250 clinical trial sites throughout the state to advance clinical research across its portfolio.
Eli Lilly has a $6.5 billion manufacturing facility in the same Generation Park development. The facility, announced in September 2025, focuses on manufacturing small-molecule medicines, including the company’s experimental oral GLP-1. Construction is set to finish in 2030.
Tell Us What You Think!